This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.  

The scientific program consists of formal lectures by experts in clinical and basic research, selected slide and poster presentations, forums and case discussions.  The official language of the symposium is English.  Simultaneous translation is not provided.

This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals. We anticipate 8,000 attendees from more than 80 countries.

Meeting Location - Virtual

We are very pleased to announce that the San Antonio Breast Cancer Symposium will take place in 2020. In response to the novel coronavirus (COVID019) global pandemic, the SABCS Executive Committee has made the decision, out of necessity to ensure the health, safety and security of all SABCS attendees and the patients and communities they serve, to hold the 2020 SABCS virtually. The dates will remain be December 8-11, 2020.  

We look forward to holding SABCS as an in-person meeting for the 2021 Symposium at the Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 USA.

Contact Information

Sharon Hill, Director, Symposia
Mays Cancer Center 
7979 Wurzbach Road, MC 8224 
San Antonio, TX 78229 USA 
Email: sabcs@uthscsa.edu
Phone: 210-450-1550 
FAX: 210-450-1560

Hours subject to change.

Tuesday, December 8
Exhibits 10:00 AM–7:00 PM
Program 8:00 AM–7:45 PM

Wednesday, December 9
Program 8:00 AM–7:45 PM
Exhibits 10:00 AM–5:00 PM

Thursday, December 10
Program 8:45 AM–4:45 PM
Exhibits 10:00 AM–5:00 PM

Friday, December 11
Program 8:15 AM–7:00 PM
Exhibits 10:00 AM–5:00 PM

Carlos L. Arteaga, UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX
Gary C. Chamness, Baylor College of Medicine, Houston, TX (ex-officio)
Margaret Foti, American Association for Cancer Research, Philadelphia, PA
Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
Sharon Hill, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)
Ismail Jatoi, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Virginia G. Kaklamani, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Kate Lathrop, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)
Ruben A. Mesa, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
C. Kent Osborne, Baylor College of Medicine, Houston, TX
Mothaffar Rimawi, Baylor College of Medicine, Houston, TX
Xiang Zhang, PhD, Baylor College of Medicine, Houston, TX

Carlos L. Arteaga, AACR (Co-Chair), UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX
Aditya Bardia, Massachusetts General Hospital, Boston, MA
Gary C. Chamness, Baylor College of Medicine, Houston, TX (ex-officio)
Chonghui Cheng, Baylor College of Medicine, Houston, TX
Bonner Cutting, Alamo Breast Cancer Foundation, San Antonio, TX
Rebecca Dent, National Cancer Center, Singapore, SINGAPORE
Suzanne AW Fuqua, Baylor College of Medicine, Houston, TX
Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA
Reshma Jagsi, MD, DPhil, University of Michigan, Ann Arbor, MI
Ismail Jatoi, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Virginia G. Kaklamani (Co-Chair), Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Kate Lathrop, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)
Eleftherios (Terry) P. Mamounas, MD, MPH, Orlando UF Health Cancer Center, Orlando, FL
Elizabeth A. Mittendorf, Dana-Farber Cancer Institute, Boston, MA
Julie R. Nangia, MD, Baylor College of Medicine, Houston, TX
C. Kent Osborne (Co-Chair), Baylor College of Medicine, Houston, TX
Charles M. Perou, University of North Carolina, Chapel Hill, NC
Susan Rafte, Community Patient Advocate, Houston, TX
Manjeet K. Rao, PhD, MSc, BSc, Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX
Andrea L. Richardson, Johns Hopkins, Washington, DC
Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX
Rachel Schiff, Baylor College of Medicine, Houston, TX
Kalliopi P. Siziopikou, MD, PhD, Northwestern University, Chicago, IL
Alastair M. Thompson, BSc (HONS), MB ChB, Baylor College of Medicine, Houston, TX
Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA
Douglas Yee, University of Minnesota, Minneapolis, MN
Xiang Zhang, Baylor College of Medicine, Houston, TX

Patient advocates wishing to apply for financial assistance for the 2020 Virtual SABCS should contact the Alamo Breast Cancer Foundation for information and an application. Applications are available online. Please see their website for more information and qualifications. Applications must be post-marked by September 1, 2020.

E-mail: sandi@alamobreastcancer.org
Web: www.alamobreastcancer.org

Susan G. Komen^® Brinker Award for Scientific Distinction

Established by the Susan G. Komen for the Cure in 1992, the Brinker Award for Scientific Distinction recognizes leading scientists for significant work in advancing research concepts and for clinical application in the fields of breast cancer research, screening or treatment. The award is presented to basic and clinical researchers who have made seminal advances in the fight against breast cancer. In addition, the award recognizes scholars for a specific contribution, a consistent pattern of contributions, or leadership in the field that has had a substantial impact on the fight against breast cancer.

The Brinker Award is to be used to further the recipients' activities in breast cancer research. This award has grown in prominence in the breast cancer community and is a marquee award for Komen for the Cure. The recipients of the Brinker Awards will deliver plenary lectures at the 2020 San Antonio Breast Cancer Symposium.

The William L. McGuire Memorial Lectureship

Dr. William L. McGuire, along with Dr. Charles A. Coltman, founded the San Antonio Breast Cancer Symposium in 1977. The William L. McGuire Memorial Lectureship was established in 1992 to commemorate the significant contributions of Dr. McGuire to oncology medicine. His research played a major role in introducing estrogen receptor assays on breast tumor tissue as a guide to treatment decisions for women with breast cancer. Breast cancer patients everywhere now receive these tests.

The lecturer is selected by the SABCS McGuire Award Committee from persons through a nomination process. The selection is based on the following criteria:

• Lecturers are respected figures with an international reputation.

• They have made significant contributions to the field of breast cancer research.

• They are known as skilled presenters.

• They present a topic of high current interest related to the diagnosis and treatment of breast cancer or to the study of its underlying   mechanisms.

AACR Outstanding Investigator Award for Breast Cancer Research, funded by The Breast Cancer Research Foundation

The AACR Outstanding Investigator Award for Breast Cancer Research is presented to an investigator no more than 50 years of age whose novel and significant work that has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of breast cancer.

AACR Distinguished Lectureship in Breast Cancer Research

The AACR Distinguished Lectureship in Breast Cancer Research has been established to recognize outstanding science that has inspired or has the potential to inspire new perspectives on the etiology, diagnosis, treatment, or prevention of breast cancer.

Abstracts, with the exception of those withheld for SABCS press conferences, will be released approximately one month prior to the symposium. The abstracts withheld for press will be released at the beginning of the day on which the relevant press conference occurs.

Reporters, producers and editors agree to the embargoes and release times stated on the news releases, the news conference schedule and other materials. Failure to abide by the embargoes will result in suspension of credentials, which will affect attendance at the current and future symposia and ability to receive advance press materials.

By allowing an abstract to be included in the 2020 San Antonio Breast Cancer Symposium media outreach program, the Presenter verifies that the abstract’s contents and its conclusions have not been and will not be published or presented in any form to the public before the start of the actual presentation. This includes, but is not limited to, non-embargoed press releases and interviews required by government agencies. Any release of material and specific non-embargoed information prior to the meeting’s embargo date as set forth by the SABCS press office could result in exclusion from the official SABCS press program.

A statement verifying your participation at the 2020 Virtual Symposium will be emailed to all attendees on Friday, December 11, 2020.

Physicians seeking CME credit for this live continuing medical education activity or a Certificate of Attendance must complete the surveys on the 2020 SABCS Mobile App.  Surveys open on December 8, 2020 and close on January 31, 2021. Certificates will be emailed once a week on the dates below after completing the evaluations and post event evaluation:

• December 18, 2020  
• January 8, 2021
•  January 15, 2021
•  January 22, 2021
•  January 29, 2021
•  February 5, 2021    

The deadline to complete you session evaluations and post survey is January 31, 2021.  To receive MOC II the form to complete is now available on our website. 

To download the App, please click here.

Sponsored by AstraZeneca